PMV Pharmaceuticals Inc (PMVP) 銘柄情報

PMVP under $2

PMVP had a great move over $3 but then lost control of the jet and sank quickly.

PMVP into the cup and handle chart setup. On radar to begin climbing the great wall of worry.

mb

$PMVP trading in the low $2's for now but at some point, this starts to firm up well into 2024+.

mb

PMVP will be under radar for a while until it catches fire and then will be seen.

mb

2022 American Society of Clinical Oncology (ASCO) Annual Meeting

JUNE 7 > Updated data from ongoing Phase 1/2 PYNNACLE trial to be presented .

PMV Pharma Shares Rise 17%; Company to Present Data on PYNNACLE Phase 1 Trial
6:46 pm ET May 26, 2022 (Dow Jones) Print

By Stephen Nakrosis


Shares of PMV Pharmaceuticals Inc. were trading higher in Thursday's after-hours market, following the company's announcement that it would be presenting data from its lead program, PC14586, at the 2022 American Society of Clinical Oncology meeting next month.

PMV said its abstract describes "preliminary outcomes from 29 patients, including 21 efficacy evaluable, from the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation." PMV said the preliminary results "represent the first clinical evidence of targeting a p53 Y220C mutation."

At 6:37 p.m. ET, PMV's shares were trading 17.79% higher at $15.56 a share. Volume at the time topped 2.1 million shares. The company's stock finished the day with a 0.92% gain, closing at $13.21 a share.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

PMVP

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.

PMVP